Journal
VETERINARY RECORD
Volume 180, Issue 2, Pages -Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/vr.103653
Keywords
-
Categories
Funding
- Ministerio de Ciencia e Innovacion, Spain [CG12010-22368-CO2-01]
- Departement d' Universitats, Recerca i Societat de la Informacio de la Generalitat de Catalunya (Spain) [2009SGR385]
- Red de Investigacion Cooperativa en Enfermedades Tropicales (RICET)
Ask authors/readers for more resources
Knowledge of how canine leishmaniosis (CanL) is being managed clinically and its epidemiology is very important, since dogs are the main reservoir of human leishmaniosis. This study reports the results obtained through a questionnaire-based survey of veterinary practitioners in Girona province, a recognised, but non-documented endemic area in northeastern Spain. The primary objective was to obtain data on the clinical management of CanL, focusing particularly on new preventive methods and therapeutic tools. The results show an extensive routine management of CanL cases and a widespread use of the CaniLeish (Virbac) vaccine and domperidone (Leisguard, Esteve). Adverse reactions were detected by a vast majority of the vaccine users (82 per cent), the most frequent being local reactions, apathy, fever and gastroenteritis. All the respondents had treated confirmed cases, and the therapeutic protocol most used was the combination of meglumine antimoniate (Glucantime, Merial) and allopurinol (Zyloric, GlaxoSmithKline).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available